Here is what Chris Bunka said to me when I asked him about what was happening: Hi Kevin, Thanks for your outreach. I understand your disappointment but as to disclosure, we are not allowed to invent things that aren't factual - and Altria will not permit us to speculate as to their reasoning or their plans. So, even if we HAD additional info that we wanted to distribute, we would only be permitted to disclose what they allow. Since they've told us nothing, we simply have no more info.
As for a way forward, we're busy as heck with many positive things in recent months and currently. Here are a couple:
- We've announced logarithmic growth in our CBD B2B business line;
- We're working on our first ever antiviral drug delivery study, to learn if our tech could be applicable in that multi-billion $ sector;
- We've announced a larger human clinical follow-up study to test for blood pressure reduction in human hypertensive volunteers. The annual hypertension drug market is a $24 billion opportunity;
- And, we've announced that a tobacco company roughly 50% larger than ALtria, British American Tobacco, is currently evaluating our technology for their own purposes.
No company is able to make everything it does a success, just as even the very best sports teams cannot win every game. We're winning at a lot of things we do, and with Altria, we don't know if they plan on going to market "one day" with our tech or not. But we've done a great job of giving our investors multiple pathways to success and we continue to pursue them all.
Thanks again for reaching out,
Chris Bunka
CEO
